Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial

Tools

Pocock, Stuart J., Ferreira, Joao Pedro, Gregson, John, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Gollop, Nicholas D., Iwata, Tomoko, Brueckmann, Martina, Januzzi, James L., Voors, Adriaan A., Zannad, Faiez and Packer, Milton (2021) Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 42 (43). 4455–4464. ISSN 0195-668X

[thumbnail of Published_Version]
Preview
 PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution Non-commercial.
Download (1MB) | Preview

Abstract

Aims: The aim of this study was to generate a biomarker-driven prognostic tool for patients with chronic HFrEF. Circulating levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) each have a marked positive relationship with adverse outcomes in heart failure with reduced ejection fraction (HFrEF). A risk model incorporating biomarkers and clinical variables has not been validated in contemporary heart failure (HF) trials. Methods and results: In EMPEROR-Reduced, 33 candidate variables were pre-selected. Multivariable Cox regression models were developed using stepwise selection for: (i) the primary composite outcome of HF hospitalization or cardiovascular death, (ii) all-cause death, and (iii) cardiovascular mortality. A total of 3730 patients were followed up for a median of 16 months, 823 (22%) patients had a primary outcome and 515 (14%) patients died, of whom 389 (10%) died from a cardiovascular cause. NT-proBNP and hs-cTnT were the dominant predictors of the primary outcome, and in addition, a shorter time since last HF hospitalization, longer time since HF diagnosis, lower systolic blood pressure, New York Heart Association (NYHA) Class III or IV, higher heart rate and peripheral oedema were key predictors (eight variables in total, all P < 0.001). The primary outcome risk score discriminated well (c-statistic = 0.73), with patients in the top 10th of risk having an event rate >9 times higher than those in the bottom 10th. Empagliflozin benefitted patients across risk levels for the primary outcome. NT-proBNP and hs-cTnT were also the dominant predictors of all-cause and cardiovascular mortality, followed by NYHA Class III or IV and ischaemic aetiology (four variables in total, all P < 0.001). The mortality risk model presented good event discrimination for all-cause and cardiovascular mortality (c-statistic = 0.69 for both). These simple models were externally validated in the BIOSTAT-CHF study, achieving similar c-statistics. Conclusions: The combination of NT-proBNP and hs-cTnT with a small number of readily available clinical variables provides prognostic assessment for patients with HFrEF. This predictive tool kit can be easily implemented for routine clinical use.

Item Type: Article
Uncontrolled Keywords: heart failure,high-sensitivity cardiac troponin t,nt-probnp,risk score,cardiology and cardiovascular medicine ,/dk/atira/pure/subjectarea/asjc/2700/2705
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 20 Dec 2021 12:30
Last Modified: 10 Jan 2023 22:36
URI: https://ueaeprints.uea.ac.uk/id/eprint/82736
DOI: 10.1093/eurheartj/ehab579

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item